Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies: A Phase 1 Double Blinded Randomized Placebo Toxicity Trial
Phase of Trial: Phase I
Latest Information Update: 14 Sep 2018
At a glance
- Drugs Idelalisib (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions
- 05 Sep 2018 Planned number of patients changed from 50 to 60.
- 05 Sep 2018 Planned End Date changed from 1 Mar 2021 to 1 Dec 2020.
- 05 Sep 2018 Status changed from not yet recruiting to recruiting.